Hyperphosphatemia - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hyperphosphatemia - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Hyperphosphatemia - Pipeline Review, H2 2015', provides an overview of the Hyperphosphatemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hyperphosphatemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperphosphatemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hyperphosphatemia Overview 8
Therapeutics Development 9
Pipeline Products for Hyperphosphatemia - Overview 9
Pipeline Products for Hyperphosphatemia - Comparative Analysis 10
Hyperphosphatemia - Therapeutics under Development by Companies 11
Hyperphosphatemia - Therapeutics under Investigation by Universities/Institutes 12
Hyperphosphatemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Hyperphosphatemia - Products under Development by Companies 16
Hyperphosphatemia - Products under Investigation by Universities/Institutes 17
Hyperphosphatemia - Companies Involved in Therapeutics Development 18
3SBio Inc. 18
Ardelyx, Inc. 19
Galenica Ltd. 20
Medice Arzneimittel Putter GmbH & Co. KG 21
OPKO Health, Inc. 22
Panion & Bf Biotech Inc 23
Sanofi 24
Spectrum Pharmaceuticals, Inc. 25
Toray Industries, Inc. 26
Hyperphosphatemia - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 33
Drug Profiles 35
colestilan chloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CPAM-11 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
fermagate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ferric citrate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
calcium succinate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
JPH-101 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
niacinamide - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
PDX-003 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
PT-20 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RDX-002 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
sevelamer carbonate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule to Target Phosphate for Hyperphosphatemia - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SPI-014 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
succharated ferric oxide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
tenapanor hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
TRK-390 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
VS-501 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
VS-505 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Hyperphosphatemia - Recent Pipeline Updates 59
Hyperphosphatemia - Dormant Projects 71
Hyperphosphatemia - Discontinued Products 72
Hyperphosphatemia - Product Development Milestones 73
Featured News & Press Releases 73
Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology 73
Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis 73
Jan 27, 2015: Velphoro receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis 74
Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch 74
Dec 04, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia (ferric citrate) Covering Orally Administrable Forms 75
Nov 19, 2014: New Drug Application Submitted For PA21 (development code) For Treatment Of Hyperphosphatemia 76
Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate 76
Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 77
Oct 23, 2014: Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014 78
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms 79
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 81
Disclaimer 82

List of Tables

Number of Products under Development for Hyperphosphatemia, H2 2015 9
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Hyperphosphatemia - Pipeline by 3SBio Inc., H2 2015 18
Hyperphosphatemia - Pipeline by Ardelyx, Inc., H2 2015 19
Hyperphosphatemia - Pipeline by Galenica Ltd., H2 2015 20
Hyperphosphatemia - Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H2 2015 21
Hyperphosphatemia - Pipeline by OPKO Health, Inc., H2 2015 22
Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H2 2015 23
Hyperphosphatemia - Pipeline by Sanofi, H2 2015 24
Hyperphosphatemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 25
Hyperphosphatemia - Pipeline by Toray Industries, Inc., H2 2015 26
Assessment by Monotherapy Products, H2 2015 27
Number of Products by Stage and Target, H2 2015 29
Number of Products by Stage and Mechanism of Action, H2 2015 31
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Hyperphosphatemia Therapeutics - Recent Pipeline Updates, H2 2015 59
Hyperphosphatemia - Dormant Projects, H2 2015 71
Hyperphosphatemia - Discontinued Products, H2 2015 72